Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database

Cancer Epidemiology

Volumn 39, Issue 4, 2015, Pages 593-599

  Duchman, Kyle R ^a   Gao, Yubo ^a   Miller, Benjamin J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Bone neoplasms mortality; Risk factors; Sarcoma, Osteosarcoma mortality; SEER Program; Survival analysis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; SOCIAL STATUS; UNIVARIATE ANALYSIS; BONE TUMOR; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; SOCIAL CLASS;

ADULT; AGED; BONE NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OSTEOSARCOMA; PROGNOSIS; RISK FACTORS; SEER PROGRAM; SOCIAL CLASS;

EID: 84938740473     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.05.001     Document Type: Article

References (34)

1. Jawad M.U., Cheung M.C., Clarke J., Koniaris L.G., Scully S.P. Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clinc Oncol 2011, 137:597-607.
2. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115:1531-1543.
3. Cortes E.P., Holland J.F., Wang J.J., Sinks L.F. Doxorubicin in disseminated osteosarcoma. JAMA 1972, 221:1132-1138.
4. Jaffe N., Paed D., Farber S., Traggis D., Geiser C., Kim B.S., et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973, 31:1367-1373.
5. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20:776-790.
6. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
7. Bacci G., Briccoli A., Rocca M., Ferrari S., Donati D., Longhi A., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003, 14:1126-1134.
8. Clark J.C., Dass C.R., Choong P.F. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008, 134:281-297.
9. Kager L., Zoubek A., Pötschger U., Kastner U., Flege S., Kempf-Bielack B., et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21:2011-2018.
10. Meyers P.A., Heller G., Healey J.H., Huvos A., Applewhite A., Sun M., et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993, 11:449-453.
11. Mialou V., Philip T., Kalifa C., Perol D., Gentet J.C., Marec-Berard P., et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer 2005, 104:1100-1109.
12. Miller B.J., Cram P., Lynch C.F., Buckwalter J.A. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am 2013, 95:e89.
13. Crawford S.M., Sauerzapf V., Haynes R., Forman D., Jones A.P. Social and geographical factors affecting access to treatment of colorectal cancer: a cancer registry study. BMJ Open 2012, 2:e000410.
14. Downing S., Ahuja N., Oyetunji T.A., Chang D., Frederick W.A. Disparity in limb-salvage surgery among sarcoma patients. Am J Surg 2010, 199:549-553.
15. Du X.L., Fang S., Coker A.L., Sanderson M., Aragaki C., Cormier J.N., et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 2006, 106:1276-1285.
16. Lee J., Hoang B.H., Ziogas A., Zell J.A. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 2010, 116:1964-1973.
17. Sun M., Abdollah F., Liberman D., Abdo A., Thuret R., Tian Z., et al. Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer 2011, 117:4277-4285.
18. Ek E.T., Ojaimi J., Kitagawa Y., Choong P.F. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival?. Int Semin Surg Oncol 2006, 3:7.
19. Grimer R., Cannon S., Taminiau A., Bielack S., Kempf-Bielack B., Windhager R., et al. Osteosarcoma over the age of forty. Eur J Cancer 2003, 39:157-163.
20. Harting M.T., Lally K.P., Andrassy R.J., Vaporciyan A.A., Cox C.S., Hayes-Jordan A., et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010, 136:561-570.
21. Longhi A., Errani C., Gonzales-Arabio D., Ferrari C., Mercuri M. Osteosarcoma in patients older than 65 years. J Clin Oncol 2008, 26:5368-5373.
22. Bieling P., Rehan N., Winkler P., Helmke K., Maas R., Fuchs N., et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996, 14:848-858.
23. Jeon D-G., Song W.S., Cho W.H., Kong C-B., Cho S.H. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma. Clin Orthop Relat Res 2014, 472:1911-1920.
24. Lindner N.J., Ramm O., Hillmann A., Roedl R., Gosheger G., Brinkschmidt C., et al. Limb salvage and outcome of osteosarcoma: The University of Muenster experience. Clin Orthop Relat Res 1999, 358:83-89.
25. Ozaki T., Flege S., Kevric M., Lindner N., Maas R., Delling G., et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003, 21:334-341.
26. Ozaki T., Flege S., Liljenqvist U., Hillmann A., Delling G., Salzer-Kuntschik M., et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 2002, 94:1069-1077.
27. Petrilli A.S., Gentil F.C., Epelman S., Lopes L.F., Bianchi A., Lopes A., et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 1991, 68:733-737.
28. Smeland S., Müller C., Alvegard T., Wiklund T., Wiebe T., Björk O., et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003, 39:488-494.
29. Saeter G., Elomaa I., Wahlqvist Y., Alvegård T., Wiebe T., Monge O., et al. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997, 273:156-160.
30. Krieger N., Chen J.T., Waterman P.D., Soobader M.-J., Subramanian S., Carson R. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol 2002, 156:471-482.
31. Nathan S.S., Healey J.H. Making a case for the socioeconomic determinacy of survival in osteosarcoma. Clin Orthop Relat Res 2013, 471:784-791.
32. Duchman K.R., Lynch C.F., Buckwalter J.A., Miller B.J. Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma. Clin Orthop Relat Res 2014, 472:2516-2525.
33. Giuffrida A.Y., Burgueno J.E., Koniaris L.G., Gutierrez J.C., Duncan R., Scully S.P. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009, 91:1063-1072.
34. Miller B.J., Lynch C.F., Buckwalter J.A. Conditional survival is greater than overall survival at diagnosis in patients with osteosarcoma and Ewing's sarcoma. Clin Orthop Relat Res 2013, 471:3398-3404.